Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978759 | 0.90 | CHKA (0.46) | PAOXSIGMAR1TDP1 | |
| SCHEMBL5241070 | 0.87 | — | — | |
| SCHEMBL8865 | 0.83 | PAOX (0.52) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9367 | 0.81 | PAOX (0.55) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6143515 | 0.81 | PAOX (0.46) | PAOXMC4RSIGMAR1ALOX15CYP1A2 | |
| SCHEMBL40839 | 0.81 | PAOX (0.46) | PAOXMC4RSIGMAR1ALOX15CYP1A2 | |
| SCHEMBL1316672 | 0.80 | PKM (0.38) | SIGMAR1ALOX15 | |
| SCHEMBL4398420 | 0.80 | DRD2 (0.43) | SIGMAR1ALOX15 | |
| SCHEMBL27905910 | 0.79 | PAOX (0.59) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL430196 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | claimed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | claimed |
| US-20240010619-A1 | SMALL MOLECULES WITH ANTIBACTERIAL ACTIVITY | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2024-01-11 | — | — | US | claimed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | claimed |
| CN-117229205-A | Preparation method and pharmaceutical application of phenyl acrylamide RHbDD1 inhibitor | 中国医学科学院基础医学研究所 | 2023-12-15 | — | — | CN | claimed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | claimed |
| US-20230174483-A1 | INDIRUBIN DERIVATIVES, AND USES THEREOF | CITY OF HOPE (US) | 2023-06-08 | — | — | US | claimed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | claimed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | claimed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | claimed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
| US-4421927-A | SKIN DISORDERS | SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) | 1983-12-20 | — | — | US | claimed |
| EP-0051514-B1 | CINNAMOYL-CINNAMIC ACID DERIVATIVE, ITS PREPARATION AND ITS USE AS A THERAPEUTIC AGENT | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1983-11-23 | — | — | EP | claimed |
| EP-0051514-A1 | Cinnamoyl-cinnamic acid derivative, its preparation and its use as a therapeutic agent | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1982-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174483-A1 | INDIRUBIN DERIVATIVES, AND USES THEREOF | HCCS, ABL1, MAP3K7 | PAOX 3131/4885MC4R 4260/4885SIGMAR1 4378/4885 |
| US-20240010619-A1 | SMALL MOLECULES WITH ANTIBACTERIAL ACTIVITY | CLPP, MRPL21, TIAL1 | PAOX 2918/4885MC4R 4740/4885SIGMAR1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.